Viewing Study NCT06221358



Ignite Creation Date: 2024-05-06 @ 8:02 PM
Last Modification Date: 2024-10-26 @ 3:18 PM
Study NCT ID: NCT06221358
Status: RECRUITING
Last Update Posted: 2024-05-09
First Post: 2024-01-02

Brief Title: Pharmacogenomics of Stimulant Treatment Response
Sponsor: University of Calgary
Organization: University of Calgary

Study Overview

Official Title: Pharmacogenomics of Stimulant Treatment Response in Children and Adolescents With Attention-Deficit Hyperactivity Disorder
Status: RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PGx-STaR
Brief Summary: The Pharmacogenomics of Stimulant Treatment Response PGx-STaR study aims to identify genetic profiles related to methylphenidate treatment outcomes in children and adolescents aged 6-17 with Attention deficithyperactivity disorder ADHD
Detailed Description: Background ADHD is a common neurodevelopmental disorder affecting children and adolescents with psychostimulants specifically slow-release methylphenidate eg Biphentin Concerta being a first-line treatment option However the response to medications varies significantly among individuals with some experiencing limited benefits or intolerable side effects Unlike other areas of psychiatry ADHD pharmacotherapy lacks genetic markers to guide treatment decisions resulting in delayed symptom relief and diminished quality of life for patients

Objectives

1 Identifying genomic profiles associated with psychostimulant treatment response and tolerability in children and adolescents with ADHD
2 Establishing a research platform for the discovery of new genetic and non-genetic markers of drug treatment outcomes relevant to mental health care in children

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: None